Effects of Intermittent Fasting Variations on Metabolic, Inflammatory, and Nutrigenomic Profiles in Prediabetes: A Randomized Controlled Trial
The Effect of Intermittent Fasting Variations on Nutrigenomic Profile, Changes in Metabolic and Inflammatory Parameters, and Body Composition in Patients With Prediabetes
1 other identifier
interventional
120
1 country
1
Brief Summary
Prediabetes is a metabolic condition associated with increased risk of type 2 diabetes and cardiovascular disease. Intermittent fasting (IF) has emerged as a potential dietary intervention to improve metabolic health, yet comparative evidence among different IF patterns remains limited. This randomized controlled trial aims to evaluate the effects of three intermittent fasting regimens-5:2 fasting, alternate-day fasting, and time-restricted feeding-compared with a control diet on metabolic parameters, inflammatory markers, body composition, and nutrigenomic profiles in adults with prediabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2026
CompletedFirst Submitted
Initial submission to the registry
February 6, 2026
CompletedFirst Posted
Study publicly available on registry
February 13, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
February 13, 2026
February 1, 2026
4 months
February 6, 2026
February 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Metabolic Profile
Change in Fasting Plasma Glucose (mg/dL)
Baseline, Week 3, and Week 6
Secondary Outcomes (4)
Lipid Profile
Baseline and Week 6
Nutrigenomics
Baseline
Body Composition
Baseline, Week 3, and Week 6
Inflammation Profile
Baseline and Week 6
Study Arms (3)
Intermittent Fasting (16:8)
EXPERIMENTAL5:2 Diet
ACTIVE COMPARATORNon Fasting
NO INTERVENTIONInterventions
Eligibility Criteria
You may qualify if:
- Patients with prediabetes, defined according to ADA criteria (fasting plasma glucose 100-125 mg/dL or 2-hour postprandial glucose 140-199 mg/dL).
- Willing to follow the fasting/diet intervention protocol for 4-6 weeks (depending on the study duration).
- Signing informed consent and willing to be randomized into one of 3 intervention groups (Monday-Thursday Fasting/5:2, Alternate-Day Fasting/ADF, or Time-Restricted Fasting/IF).
You may not qualify if:
- Diagnosis of type 2 diabetes mellitus.
- Currently undergoing antidiabetic drug therapy (e.g., metformin, sulfonylurea, insulin).
- Has a severe chronic disease (kidney failure, liver failure, heart failure, or eating disorder).
- Pregnancy or breastfeeding.
- History of eating disorders (anorexia nervosa, bulimia nervosa, or binge eating disorder).
- Taking medications that affect glucose metabolism (e.g., systemic steroids, atypical antipsychotics, etc.). Diagnosis of type 2 diabetes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Internal Medicine - Endocrinology Division, Faculty of Medicine, Universitas Sumatera Utara / RSUP H. Adam Malik Medan
Medan, North Sumatera, Indonesia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof
Study Record Dates
First Submitted
February 6, 2026
First Posted
February 13, 2026
Study Start
February 1, 2026
Primary Completion (Estimated)
May 31, 2026
Study Completion (Estimated)
June 30, 2026
Last Updated
February 13, 2026
Record last verified: 2026-02